Emergent BioSolutions
TrialRedline tracks 13 clinical trials sponsored by Emergent BioSolutions: 4 Phase 3, 1 Phase 2 / 3, 8 Phase 2.
Company identity has not yet been verified
13Trials in this database
1Recorded changes · last 12 months
0Recruiting trials
Which trial dates moved later?
Emergent BioSolutions clinical trials we track
Check company identity sourcePhase 3 4 trials
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| VELOCITY: An Anthrax Vaccine Clinical StudyNCT03877926 | AV7909, BioThrax | Completed | 2020-08-06Actual |
| Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsNCT01491607 | BioThrax | Completed | 2012-05Actual |
| VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVNCT01158157 | ACAM2000 | Completed | 2012-02-14Actual |
| Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)NCT01311674 | hepatitis B vaccine | Terminated | 2011-03-11Actual |
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Trial details
- Registry ID
- NCT01491607
- Drugs studied
- BioThrax
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
Trial details
- Registry ID
- NCT01158157
- Drugs studied
- ACAM2000
Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)
Trial details
- Registry ID
- NCT01311674
- Drugs studied
- hepatitis B vaccine
Phase 2 / 3 1 trial
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| HuMax-CD4 in Non-Cutaneous T-Cell LymphomaNCT00877656 | HuMax-CD4 | Completed | 2006-01Actual |
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
Trial details
- Registry ID
- NCT00877656
- Drugs studied
- HuMax-CD4
Phase 2 8 trials
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
Trial details
- Registry ID
- NCT04067011
- Drugs studied
- AV7909, Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Trial details
- Registry ID
- NCT03315104
- Drugs studied
- FLU-IGIV
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Ciprofloxacin BioThrax Co-Administration Study
Trial details
- Registry ID
- NCT01753115
- Drugs studied
- BioThrax, Ciprofloxacin
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
Trial details
- Registry ID
- NCT00679172
- Drugs studied
- Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of of 1.7 x 10^10 CFU (Cohort 4)
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
Trial details
- Registry ID
- NCT00053495
- Drugs studied
- Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
Trial details
- Registry ID
- NCT00053482
- Drugs studied
- ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
Trial details
- Registry ID
- NCT00893516
- Drugs studied
- CHOP, CHOP + CD4
Drugs in these trials
Names as written in the registry records.
- BioThrax 4 trials
- AV7909 3 trials
- ACAM2000 1 trial
- ACAM2000 Smallpox Vaccine 1 trial
- CHOP 1 trial
- CHOP + CD4 1 trial
- Ciprofloxacin 1 trial
- Ciprofloxacin 500Mg Tablet 1 trial
- Dose of 1.1 x 10^10 CFU (Cohort 3) 1 trial
- Dose of 5.0 x 10^9 CFU (Cohort 1) 1 trial
- Dose of 7.5 x 10^9 CFU (Cohort 2) 1 trial
- Dose of of 1.7 x 10^10 CFU (Cohort 4) 1 trial
Show 7 more
- Doxycycline 100Mg Tablet 1 trial
- FLU-IGIV 1 trial
- hepatitis B vaccine 1 trial
- HuMax-CD4 1 trial
- Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® 1 trial
- vaccinia virus (calf lymph): Dryvax 1 trial
- Vaccinia virus: ACAM2000 smallpox vaccine 1 trial
VELOCITY: An Anthrax Vaccine Clinical Study
NCT03877926 · Emergent BioSolutions
Actual enrollment decreased by 173 participants
Before: 3862 participants (actual). After: 3689 participants (actual).